Delanghe J R, De Winter H A, De Buyzere M L, Camaert J J, Martens F E, De Praeter C
Department of Clinical Chemistry, University Hospital, Gent, Belgium.
Clin Chim Acta. 1990 Dec 14;193(3):125-35. doi: 10.1016/0009-8981(90)90244-m.
A new two-site immunoenzymometric method using monoclonal antibodies was developed for measuring CK-BB mass concentrations in cerebrospinal fluid (CSF). Within- and between-assay coefficient of variation values for the method varied between 6 and 9%. Assay results are not affected by presence of sulfate and sialic acid groups on the enzyme. In comparison to catalytic activity measurements, a steady decline in the enzyme's specific activity was observed after acute head trauma. Repetitive measurements of CK-BB mass concentration in cerebrospinal fluid during the first 24 h after trauma enabled the estimation of brain lesion size. Clinical outcome of acute head trauma patients evaluated by Glasglow Outcome Scale, correlated well with cumulative CK-BB release after trauma. Also in neonates, CK-BB determinations in CSF correlated well with clinical findings.
开发了一种使用单克隆抗体的新型双位点免疫酶测定法，用于测量脑脊液（CSF）中的肌酸激酶脑型（CK-BB）质量浓度。该方法的批内和批间变异系数值在6%至9%之间。该测定结果不受酶上硫酸根和唾液酸基团的影响。与催化活性测量相比，急性头部创伤后观察到该酶的比活性稳步下降。创伤后24小时内重复测量脑脊液中的CK-BB质量浓度，能够估计脑损伤大小。通过格拉斯哥预后量表评估的急性头部创伤患者的临床结果与创伤后累积CK-BB释放密切相关。同样在新生儿中，脑脊液中CK-BB的测定结果与临床发现密切相关。
